Why Do I Bloat After a GLP-1? What the Labels and Trials Report

Bloating is a listed side effect of GLP-1 medicines, not something unusual. The US labels for Wegovy (semaglutide), Zepbound (tirzepatide) and Saxenda (liraglutide) all list abdominal distension, burping (eructation) and gas (flatulence) among the adverse reactions that were more common than with placebo in their weight-management trials. All three labels also state that the drug delays gastric emptying.

What the labels do not do is pin bloating on a single cause. This article sets out what they and the trials report: how often, when, and which abdominal symptoms the labels treat as reasons to contact a doctor.

How often the trials reported it

These figures are from each label's table of adverse reactions in its weight-management trials. They come from different trials and are not a ranking of the drugs.

Two things stand out. Bloating-type symptoms were reported in a minority of participants, well below nausea, which affected 44% on Wegovy, up to 29% on Zepbound and 39% on Saxenda in the same tables. And placebo groups reported them too, so not every episode of bloating on these drugs is caused by the drug.

Overall, gastrointestinal adverse reactions of any kind were reported by 73% of Wegovy-treated adults against 47% on placebo, by 56% at each Zepbound dose against 30% on placebo, and by about 68% on Saxenda against 39% on placebo, according to the labels.

Why it might happen

Each label states, in its pharmacology or warnings section, that the drug delays gastric emptying: food leaves the stomach more slowly. The labels list this effect and, separately, list abdominal distension, burping and gas as adverse reactions. They do not state that one causes the other, and no label gives a mechanism for bloating specifically.

Investigational drugs in the same family show the same pattern. In the TRIUMPH-2 trial of retatrutide, gastrointestinal adverse events were the most frequently reported and more common than with placebo (Bellido 2026).

When it tends to happen

• During dose increases. The Zepbound label says the majority of nausea, vomiting and diarrhoea events occurred during dose escalation and decreased over time. A pooled analysis of the semaglutide 2.4 mg STEP 1–3 trials found most gastrointestinal adverse events were mild to moderate, transient, and most frequent during or shortly after dose escalation (Wharton 2022).

• Usually not severe. In that pooled analysis, 99.5% of gastrointestinal events on semaglutide were non-serious and 4.3% of participants stopped treatment because of them (Wharton 2022).

• Sometimes severe. The labels nevertheless carry a warning for severe gastrointestinal adverse reactions, reported in 4.1% on Wegovy against 0.9% on placebo, up to 3.1% on Zepbound against 1%, and 4.8% on Saxenda against 1.4%. All three labels say the drug is not recommended in people with severe gastroparesis.

Symptoms the labels treat as warning signs

Some abdominal symptoms on these labels point to complications rather than ordinary side effects:

• Pancreatitis. The Wegovy and Zepbound labels describe persistent severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, as the sign to look for; if pancreatitis is suspected the drug is stopped.

• Gallbladder disease. All three labels warn about gallstones and gallbladder inflammation and call for gallbladder studies if they are suspected; in Wegovy's adult weight-management trials, gallstones were reported by 1.6% on the drug against 0.7% on placebo.

• Bowel obstruction. Postmarketing reports on all three labels include ileus, intestinal obstruction and severe constipation including faecal impaction.

• Dehydration and kidney injury. Labels link vomiting and diarrhoea to volume depletion and acute kidney injury.

• Before surgery. Because of delayed gastric emptying, the labels note rare reports of pulmonary aspiration under general anaesthesia or deep sedation, and Saxenda's label tells patients to inform their healthcare providers of any planned surgery or procedure.

These are reasons to contact the prescriber or seek urgent care, not to manage alone.

What this means for research and compounded products

Everything above comes from approved products tested in controlled trials. Compounded and research-grade versions have no label of their own and no trial data behind their specific formulation. The semaglutide side effects, tirzepatide side effects and retatrutide side effects guides cover the wider adverse-event picture for each compound, and the semaglutide, tirzepatide and liraglutide profiles hold the full research summaries.

If you keep a record of symptoms alongside doses, a log with dates makes a conversation with the prescriber more specific. The Peptide Library tracker can hold both.

Frequently asked questions

Is bloating a normal side effect of GLP-1 medicines?

Abdominal distension is a listed adverse reaction on the Wegovy, Zepbound and Saxenda labels, reported in roughly 3–7% of trial participants on the drug and 2–5% on placebo.

Does GLP-1 bloating go away?

The labels and pooled trial data report that most gastrointestinal side effects were transient and most common around dose increases. They do not give a timeline for bloating specifically. The prescriber is the person to ask about persistent symptoms.

Why do GLP-1 medicines cause burping?

The labels list eructation (burping) as an adverse reaction and separately state that the drugs delay gastric emptying. They do not say one causes the other.

When is bloating on a GLP-1 a concern?

The labels treat persistent severe abdominal pain, especially radiating to the back, severe constipation, signs of bowel obstruction, and persistent vomiting or diarrhoea as warning signs. Contact the prescriber or seek urgent care.